Effects of heat-processed ginseng and its active component ginsenoside 20(S)-Rg3 on the progression of renal damage and dysfunction in type 2 diabetic otsuka long-evans tokushima fatty rats

Biological and Pharmaceutical Bulletin

Volumn 33, Issue 6, 2010, Pages 1077-1081

  Kang, Ki Sung ^a   Yamabe, Noriko ^a   Kim, Hyun Young ^b   Park, Jeong Hill ^c   Yokozawa, Takako ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Gyeongsang National University   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Ginsenoside 20(s) Rg3; Heat processed ginseng; Renal damage; Type 2 diabetic rat

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; CHOLESTEROL; CREATININE; GINSENG EXTRACT; GINSENOSIDE RG 3; GLUCOSE; INDUCIBLE NITRIC OXIDE SYNTHASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE COURSE; GLUCOSE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LIPID PEROXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; OXIDATIVE STRESS; PRIMARY PREVENTION; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GINSENOSIDES; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY DISEASES; LIPID PEROXIDATION; LIPIDS; LYSINE; MALE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PANAX; PHYTOTHERAPY; PLANT EXTRACTS; PROTEINURIA; RATS; RATS, INBRED OLETF; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 77953397753     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.33.1077     Document Type: Article

References (36)

1. Gesler W. M., Soc. Sci. Med., 34, 735-746 (1992).
2. Winslow L. C., Kroll D. J., Arch. Intern. Med., 158, 2192-2199 (1998).
3. Bent S., Ko R., Am. J. Med., 116, 478-185 (2004).
4. Cefalu W. T., Ye J., Wang Z. Q., Endocr. Metab. Immune Disord. Drug Targets, 8, 78-81 (2008).
5. Yin J., Zhang H., Ye J., Endocr. Metab. Immune Disord. Drug Targets, 8, 99-111 (2008).
6. Attele A. S., Wu J. A., Yuan C. S., Biochem. Pharmacol., 58, 1685-1693 (1999).
7. Yokozawa T., Kang K. S., Yamabe N., Kim H. Y., Drug Discov. Ther., 1, 30-44 (2007).
8. Kim W. Y., Kim J. M., Han S. B., Lee S. K., Kim N. D., Park M. K., Kim C. K., Park J. H., J. Nat. Prod., 63, 1702-1704 (2000).
9. Kang K. S., Yamabe N., Kim H. Y., Park J. H., Yokozawa T., Eur. J. Pharmacol., 591, 266-272 (2008).
10. Kim H. Y., Kang K. S., Yamabe N., Yokozawa T., Am. J. Chin. Med., 36, 989-1004 (2008).
11. American Diabetes Association, Diabetes Care, 28, S37-S42 (2005).
12. Nakai S., Masakane I., Shigematsu T., Hamano T., Yamagata K., Watanabe Y., Itami N., Ogata S., Kimata N., Shinoda T., Syouji T., Suzuki K., Taniguti M., Tsuchida K., Nakamoto H., Nishi S., Nishi H., Hashimoto S., Hasegawa T., Hanafusa N., Fujii N., Marubayashi S., Morita O., Wakai K., Wada A., Iseki K., Tsubakihara Y., Ther. Apher. Dial., 13, 457-504 (2009).
13. Yamabe N., Yokozawa T., J. Pharm. Pharmacol., 58, 535-545 (2006).
14. Yokozawa T., Satoh A., Nakagawa T., Yamabe N., Am. J. Chin. Med., 34, 307-321 (2006).
15. Kim C. S., Sohn E. J., Kim Y. S., Jung D. H., Jang D. S., Lee Y. M., Kim D. H., Kim J. S., J. Ethnopharmacol., 111, 240-247 (2007).
16. Vuksan V, Sung M. K., Sievenpiper J. L., Stavro P. M., Jenkins A. L., Di Buono M., Lee K. S., Leiter L. A., Nam K. Y., Arnason J. T., Choi M., Naeem A., Nutr. Metab. Cardiovasc. Dis., 18, 46-56 (2008).
17. Nagai R., Unno Y., Hayashi M. C., Masuda S., Hayase F., Kinae N., Horiuchi S., Diabetes, 51, 2833-2839 (2002).
18. Kang K. S., Yamabe N., Kim H. Y., Okamoto T., Sei Y., Yokozawa T., J. Ethnopharmacol., 113, 225-232 (2007).
19. Oura H., Hiai S., Odaka Y., Yokozawa T., J. Biochem. (Tokyo), 77, 1057-1065 (1975).
20. Kawano K., Hirashima T., Mori S., Saitoh Y., Kurosumi M., Natori T., Diabetes, 41, 1422-1428 (1992).
21. Naito C., Yamanaka T., Jpn. J. Geriat., 15, 187-191 (1978).
22. Turk H. M., Sevinc A., Camci C., Cigli A., Buyukberber S., Savli H., Bayraktar N., Acta Diabetol., 39, 117-122 (2002).
23. Schrijvers B. F., De Vriese A. S., Flyvbjerg A., Endocr. Rev., 25, 971-1010 (2004).
24. Kadkhodaee M., Qasemi A., Clin. Exp. Pharmacol. Physiol., 31, 842-846 (2004).
25. Lehmann R., Schleicher E. D., Clin. Chim. Acta, 297, 135-144 (2000).
26. Nishikawa T., Edelstein D., Du X. L., Yamagishi S., Matsumura T., Kaneda Y., Yorek M. A., Beebe D., Oates P. J., Hammes H., Giardino I., Brownlee M., Nature (London), 404, 787-790 (2000).
27. Maritim A. C., Sanders R. A., Watkins J. B. 3rd, J. Biochem. Mol. Tox-icol., 17, 24-38 (2003).
28. Sharma S., Kulkarni S. K., Chopra K., Clin. Exp. Pharmacol. Physiol., 33, 940-945 (2006).
29. Wendt T., Tanji N., Guo J., Hudson B. I., Bierhaus A., Ramasamy R., Arnold B., Nawroth P. P., Yan S. F., D'Agati V, Schmidt A. M., J. Am. Soc. Nephrol., 14, 1383-1395 (2003).
30. Williams M. E., Am. J. Kidney Dis., 41, S42-S47 (2003).
31. Cooper M. E., Diabetologia, 44, 1957-1972 (2001).
32. Tuttle K. R., Johnson E. C., Cooney S. K., Anderberg R. J., Johnson E. K., Clifton G. D., Meek R. L., Kidney Int., 67, 953-968 (2005).
33. Nagai R., Ikeda K., Higashi T., Sano H., Jinnouchi Y., Araki T., Horiuchi S., Biochem. Biophys. Res. Commun., 234, 167-172 (1997).
34. Seo Y. S., Kim J. H., Jo N. Y., Choi K. M., Baik S. H., Park J. J., Kim J. S., Byun K. S., Bak Y. T., Lee C. H., Kim A., Yeon J. E., J. Gas-troenterol. Hepatol., 23, 102-109 (2008).
35. Lee H. J., Lee Y. H., Park S. K., Kang E. S., Kim H. J., Lee Y. C., Choi C. S., Park S. E., Ahn C. W., Cha B. S., Lee K. W., Kim K. S., Lim S. K., Lee H. C., Metabolism, 58, 1170-1177 (2009).
36. Lim S., Yoon J. W., Choi S. H., Cho B. J., Kim J. T., Chang H. S., Park H. S., Park K. S., Lee H. K., Kim Y. B., Jang H. C., Metabolism, 58, 8-15 (2009).